NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT00961571 2025-02-12
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
Phase 2 Terminated
NCT00936832 2022-08-30
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Withdrawn
NCT03909724 2020-11-13
SUNRISE-CRC
Amsterdam UMC, location VUmc
Phase 2/3 Unknown
NCT00806663 2019-02-06
FOLFIRI and Sunitinib in Metastatic Colorectal Cancer
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT00361244 2017-02-17
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT00599924 2015-07-15
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00457691 2015-03-30
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
Pfizer
Phase 3 Completed
NCT00609622 2012-10-11
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT00668863 2011-10-17
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
Pfizer
Phase 2 Completed
NCT00631410 2011-03-16
Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer
Pfizer
Phase 1 Completed
NCT00077987 2007-01-11
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Pfizer
Phase 2 Completed